Hennigsdorf, Germany 

Loma Therapeutics and Pantherna Therapeutics are pleased to announce a new collaboration aimed at accelerating the development of next-generation immunotherapies.

This joint initiative brings together Loma’s innovative HPV immunotherapy technology andPantherna’s cutting-edge non-viral Lipid Nanoparticle (LNP) delivery platform. By combining our expertise, Pantherna is proud to support Loma’s mission to develop safer and more effective treatments for HPV-related diseases.

We are excited about the potential of this collaboration and look forward to driving innovation in immunotherapy.